Becton Dickinson and Co (BDX) Position Reduced by Reliant Investment Management LLC

Reliant Investment Management LLC lessened its stake in Becton Dickinson and Co (NYSE:BDX) by 0.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,000 shares of the medical instruments supplier’s stock after selling 80 shares during the quarter. Becton Dickinson and makes up about 2.7% of Reliant Investment Management LLC’s portfolio, making the stock its 24th biggest holding. Reliant Investment Management LLC’s holdings in Becton Dickinson and were worth $2,704,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. IMS Capital Management bought a new stake in shares of Becton Dickinson and in the 3rd quarter worth approximately $29,000. Oregon Public Employees Retirement Fund boosted its position in shares of Becton Dickinson and by 22,485.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 6,545,502 shares during the last quarter. Sontag Advisory LLC bought a new position in shares of Becton Dickinson and in the 4th quarter worth $43,000. JCIC Asset Management Inc. bought a new position in shares of Becton Dickinson and in the 4th quarter worth $54,000. Finally, Signet Investment Advisory Group Inc. bought a new position in shares of Becton Dickinson and in the 4th quarter worth $56,000. 84.80% of the stock is owned by institutional investors.

Shares of BDX traded down $1.26 during midday trading on Monday, hitting $238.86. The stock had a trading volume of 9,563 shares, compared to its average volume of 1,025,902. Becton Dickinson and Co has a twelve month low of $208.62 and a twelve month high of $265.87. The company has a market capitalization of $64.61 billion, a price-to-earnings ratio of 21.69, a P/E/G ratio of 1.69 and a beta of 1.21. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.97 and a quick ratio of 0.62.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.12. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The company’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter last year, the business posted $2.48 EPS. Sell-side analysts anticipate that Becton Dickinson and Co will post 12.1 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 29th. Investors of record on Friday, March 8th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.29%. The ex-dividend date is Thursday, March 7th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

BDX has been the topic of several recent research reports. Morgan Stanley reduced their price target on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 2nd. TheStreet downgraded Becton Dickinson and from a “b+” rating to a “c+” rating in a research note on Friday, December 7th. Raymond James dropped their price target on Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, March 19th. UBS Group assumed coverage on Becton Dickinson and in a research note on Tuesday, November 27th. They issued a “neutral” rating and a $260.00 price target on the stock. Finally, Citigroup dropped their price target on Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating on the stock in a research note on Wednesday, January 2nd. Five research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $255.75.

In related news, CEO Vincent A. Forlenza sold 8,309 shares of Becton Dickinson and stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $255.13, for a total value of $2,119,875.17. Following the sale, the chief executive officer now owns 222,785 shares of the company’s stock, valued at $56,839,137.05. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Vincent A. Forlenza sold 11,340 shares of Becton Dickinson and stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $250.40, for a total value of $2,839,536.00. Following the completion of the sale, the chief executive officer now directly owns 227,250 shares in the company, valued at approximately $56,903,400. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,684 shares of company stock worth $7,518,574. 0.12% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Becton Dickinson and Co (BDX) Position Reduced by Reliant Investment Management LLC” was first published by WKRB News and is owned by of WKRB News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.wkrb13.com/2019/03/25/becton-dickinson-and-co-bdx-position-reduced-by-reliant-investment-management-llc.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: Straddles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.